Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, witho...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1176309/full |
| _version_ | 1827974843036860416 |
|---|---|
| author | Elham Sajjadi Elham Sajjadi Elena Guerini-Rocco Elena Guerini-Rocco Elisa De Camilli Oriana Pala Giovanni Mazzarol Konstantinos Venetis Mariia Ivanova Nicola Fusco Nicola Fusco |
| author_facet | Elham Sajjadi Elham Sajjadi Elena Guerini-Rocco Elena Guerini-Rocco Elisa De Camilli Oriana Pala Giovanni Mazzarol Konstantinos Venetis Mariia Ivanova Nicola Fusco Nicola Fusco |
| author_sort | Elham Sajjadi |
| collection | DOAJ |
| description | The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, without gene amplification) tumors is challenged by methodological and analytical variables that might influence the sensitivity and reproducibility of HER2 testing. To open all possible therapeutic opportunities for HER2-low breast cancer patients the implementation of more accurate and reproducible testing strategies is mandatory. Here, we provide an overview of the existing barriers that may trouble HER2-low identification in breast cancer and discuss practical solutions that could enhance HER-low assessment. |
| first_indexed | 2024-04-09T20:00:55Z |
| format | Article |
| id | doaj.art-74a5081e0670443d91e62b68696a9dd0 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-04-09T20:00:55Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-74a5081e0670443d91e62b68696a9dd02023-04-03T05:03:45ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2023-04-011010.3389/fmolb.2023.11763091176309Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal testElham Sajjadi0Elham Sajjadi1Elena Guerini-Rocco2Elena Guerini-Rocco3Elisa De Camilli4Oriana Pala5Giovanni Mazzarol6Konstantinos Venetis7Mariia Ivanova8Nicola Fusco9Nicola Fusco10Department of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, ItalyThe introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, without gene amplification) tumors is challenged by methodological and analytical variables that might influence the sensitivity and reproducibility of HER2 testing. To open all possible therapeutic opportunities for HER2-low breast cancer patients the implementation of more accurate and reproducible testing strategies is mandatory. Here, we provide an overview of the existing barriers that may trouble HER2-low identification in breast cancer and discuss practical solutions that could enhance HER-low assessment.https://www.frontiersin.org/articles/10.3389/fmolb.2023.1176309/fullbreast cancerHER2HER2-lowpathologyprecision medicineimmunohistochemistry |
| spellingShingle | Elham Sajjadi Elham Sajjadi Elena Guerini-Rocco Elena Guerini-Rocco Elisa De Camilli Oriana Pala Giovanni Mazzarol Konstantinos Venetis Mariia Ivanova Nicola Fusco Nicola Fusco Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test Frontiers in Molecular Biosciences breast cancer HER2 HER2-low pathology precision medicine immunohistochemistry |
| title | Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test |
| title_full | Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test |
| title_fullStr | Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test |
| title_full_unstemmed | Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test |
| title_short | Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test |
| title_sort | pathological identification of her2 low breast cancer tips tricks and troubleshooting for the optimal test |
| topic | breast cancer HER2 HER2-low pathology precision medicine immunohistochemistry |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1176309/full |
| work_keys_str_mv | AT elhamsajjadi pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT elhamsajjadi pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT elenaguerinirocco pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT elenaguerinirocco pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT elisadecamilli pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT orianapala pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT giovannimazzarol pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT konstantinosvenetis pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT mariiaivanova pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT nicolafusco pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest AT nicolafusco pathologicalidentificationofher2lowbreastcancertipstricksandtroubleshootingfortheoptimaltest |